Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Urodynamix Technologies reviews strategic alternatives for sale of company's assets

Urodynamix Technologies Ltd. today announces that its Board of Directors has initiated a process to review strategic alternatives including the sale of part of or all of the Company's assets.

10 Dec 2009

CPRIT awards $2 million grant to study prostate cancer

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded its initial grant for a First-Time, Tenure Track Faculty Member to the University of Texas Southwestern Medical Center in Dallas.

10 Dec 2009

Today's opinions and editorials

The language in our amendment is completely consistent with the Hyde Amendment, which in the 33 years since its passage has done nothing to inhibit private health insurers from offering abortion coverage. There is no reason to believe that a continuation of this policy would suddenly create undue hardship for the insurance industry — or for those who wish to use their private insurance to pay for an abortion (Rep. Bart Stupak, 12/8).

9 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

Xanthohumol compound may aid in preventing prostate cancer

The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer.

9 Dec 2009

Daily dose of pistachios may help reduce risk of lung cancer

A diet that incorporates a daily dose of pistachios may help reduce the risk of lung and other cancers, according to data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9.

9 Dec 2009

MCG receives $1.8M stimulus grant

It's a $1.8 million shot in the arm to the largest grant the Medical College of Georgia has ever received.

8 Dec 2009

ERSPC study shows PSA screening reduced prostate cancer deaths by 20%

The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality has been given a boost with new data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This shows the true impact to be far higher than previously reported - up to 31%.

8 Dec 2009

Exercise can reduce overall mortality rates in patients with prostate cancer, according to findings

As little as 15 minutes of exercise a day can reduce overall mortality rates in patients with prostate cancer, according to findings presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held here, Dec. 6-9, 2009.

8 Dec 2009

Data shows strong inverse association between coffee consumption and advanced prostate cancer

While it is too early for physicians to start advising their male patients to take up the habit of regular coffee drinking, data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference revealed a strong inverse association between coffee consumption and the risk of lethal and advanced prostate cancers.

8 Dec 2009

Regular sexual activity can help improve the overall health in men

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released the top ten reasons regular sexual activity can help improve men’s overall health. From decreased blood pressure to more restful sleep, sexual activity is essential for maintaining bodily functions as well as overall health and well-being.

7 Dec 2009

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009

Gamma Labs sponsors the Charles Evans PCF Pro/Am Tour

On December 1, 2009 at the annual Prostate Cancer Foundation Annual Dinner, the organization acknowledged its sponsors and provided insight of the year’s events and milestones. Gamma Labs, a leading nutritional supplement company, was recognized as one of the organization’s sponsors. Gamma Labs is pleased to announce today plans to continue support of this organization. Gamma Labs serves as a sponsor for the Charles Evans PCF Pro/Am Tour, an annual event that benefits the Prostate Cancer Foundation.

5 Dec 2009

Results from Phase III pivotal study of FIRMAGON presented

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.

4 Dec 2009

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") announced today that the US Patent and Trademark Office has allowed its patent application on a system for automation of the initial stages of the manufacture of the Company's DCVax® therapeutic cancer vaccines.

4 Dec 2009